Table 6.
Compound no | Compound name | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor | Log Kp (Skin permeation) (cm/s) |
---|---|---|---|---|---|---|---|
1 | Ergost-25-ene-3,6-dione, 5,12-dihydroxy-, (5.alpha.,12.beta.)- | No | No | No | No | No | − 5.18 |
2 | Aspidospermidin-17-Ol, 1-acetyl-16-methoxy- | No | No | No | Yes | No | − 6.42 |
3 | 2-[3,4-dichlorophenyl]-4-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]-6-[trichloromethyl]-S-triazine | No | Yes | Yes | Yes | Yes | − 5.03 |
4 | Dihydroartemisinin, 10-O-(t-butyloxy)- | Yes | No | No | No | No | − 5.24 |
5 | 3-[(2-fluoroanilino)methyl]-5-(2-methoxyphenyl)-1,3,4-oxadiazole-2(3 h)-thione | Yes | Yes | Yes | No | Yes | − 5.44 |
6 | 2(1H)-naphthalenone, 5-[2-(3-furanyl)ethyl]octahydro-1,5,6,8a-tetramethyl-, | No | No | No | Yes | No | − 4.33 |
7 | 4H-1-benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-3,5-dihydroxy-7-methoxy- | Yes | No | Yes | Yes | Yes | − 6.61 |
8 | 2-butenoic acid, 2-methyl-, 4,4a,5,6,7,8,8a,9-octahydro-8a-hydroxy-3,4a,5-trimethylnaphtho[2,3-b]furan-6-yl ester | No | No | No | Yes | No | − 5.51 |
9 | Benzonitrile, 4-(4-ethylcyclohexyl)-, trans- | No | No | Yes | Yes | No | − 4.07 |
10 | 1-(2-adamantylidene) semicarbazide | No | No | No | No | No | − 6.85 |
11 |
Doxorubicin (synthetic drug) |
No | No | No | No | No | − 8.71 |